title: Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.
abstract: OBJECTIVE
  Patients with primary cutaneous melanoma with a Breslow thickness > or = 1.5 mm have only a 30% to 70% probability of survival after surgery, and no adjuvant therapy has so far improved this outcome. Since interferon alfa-2a (IFNalpha2a) exhibits antitumor activity in metastatic melanoma, we investigated whether adjuvant IFNalpha2a diminishes the occurrence of metastases and thus prolongs disease-free survival in melanoma patients after excision of the primary tumor.
  
  
  METHODS
  In a prospective randomized study, 311 melanoma patients with a Breslow thickness > or = 1.5 mm were assigned to either adjuvant IFNalpha2a treatment (n = 154) or observation (n = 157) after excision of the primary tumor. IFNalpha2a was given daily at a dose of 3 mIU subcutaneously (s.c.) for 3 weeks (induction phase), after which a dose of 3 mIU s.c. three times per week was given over 1 year (maintenance phase).
  
  
  RESULTS
  Prolonged disease-free survival was observed in patients treated with IFNalpha2a versus those who underwent surgery alone. This difference was significant (P = .02) for all patients enrolled onto the study (intention-to-treat analysis) at a mean observation time of 41 months. Subgroup analysis showed that Breslow tumor thickness had no influence on treatment results in the groups of patients investigated.
  
  
  CONCLUSIONS
  Adjuvant IFNalpha2a treatment diminishes the occurrence of metastases and thus prolongs disease-free survival in resected primary stage II cutaneous melanoma patients.
authors.affiliation: Department of Dermatology, University of Vienna, Austria. pia@akh-wien.ac.at
authors.forename: H
authors.initials: H
authors.lastname: Pehamberger
authors.forename: H P
authors.initials: HP
authors.lastname: Soyer
authors.forename: A
authors.initials: A
authors.lastname: Steiner
authors.forename: R
authors.initials: R
authors.lastname: Kofler
authors.forename: M
authors.initials: M
authors.lastname: Binder
authors.forename: P
authors.initials: P
authors.lastname: Mischer
authors.forename: W
authors.initials: W
authors.lastname: Pachinger
authors.forename: J
authors.initials: J
authors.lastname: Auböck
authors.forename: P
authors.initials: P
authors.lastname: Fritsch
authors.forename: H
authors.initials: H
authors.lastname: Kerl
authors.forename: K
authors.initials: K
authors.lastname: Wolff
mesh_terms: D000276:Adjuvants, Immunologic; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D008545:Melanoma / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins